BLUEBIRD BIO, INC. for BLUEBIRD BIO, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 16, 2024 | $140,000 | Replaced |
| 4th Quarter - Amendment | Apr 3, 2024 | $140,000 | Replaced |
| 4th Quarter - Amendment | Apr 4, 2024 | $140,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 2666 - MVP Act Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-P) CMMI sought bluebird input on potential gene therapy demo for sickle cell disease beneficiaries of Medicaid
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINA HARTMAN | — |
| KRISTIN WOLFF | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.